The ADNI Administrative Core: Ensuring ADNI's success and informing future AD clinical trials
The Alzheimer's Disease Neuroimaging Initiative (ADNI) Administrative Core oversees and coordinates all ADNI activities, to ensure the success and maximize the impact of ADNI in advancing Alzheimer's disease (AD) research and clinical trials. It manages finances and develops policies for data sharing, publications using ADNI data, and access to ADNI biospecimens. The Core develops and executes pilot projects to guide future ADNI activities and identifies key innovative methods for inclusion in ADNI. For ADNI4, the Administrative Core collaborates with the Engagement, Clinical, and Biomarker Cores to develop and evaluate novel, digital methods and infrastructure for participant recruitment, screening, and assessment of participants. The goal of these efforts is to enroll 500 participants, including > 50% from underrepresented populations, 40% with mild cognitive impairment, and 80% with elevated AD biomarkers. This new approach also provides a unique opportunity to validate novel methods. HIGHLIGHTS: The Alzheimer's Disease Neuroimaging Initiative (ADNI) Administrative Core oversees and coordinates all ADNI activities. The overall goal is to ensure ADNI's success and help design future Alzheimer's disease (AD) clinical trials. A key innovation is data sharing without embargo to maximize scientific impact. For ADNI4, novel, digital methods for recruitment and assessment were developed. New methods are designed to improve the participation of underrepresented populations.
Authors
- Winnie Kwang
- Catherine Conti
- Juliet Fockler
- Diana Truran (ORCID: https://orcid.org/0000-0001-7159-2216)
- Miriam T. Ashford (ORCID: https://orcid.org/0000-0003-4045-6435)
- Robert C. Green
- Derek Flenniken
- Melanie J. Miller (ORCID: https://orcid.org/0000-0002-7189-1109)
- Rachel L. Nosheny (ORCID: https://orcid.org/0000-0003-4995-8319)
- Dallas P. Veitch (ORCID: https://orcid.org/0000-0002-9918-0640)
- Adam Diaz
- M W Weiner
- Shaveta Kanoria
Institutions
- Boston Medical Center (US)
- San Francisco VA Medical Center (US)
- Harvard University (US)
- University of California, San Francisco (US)
- University Medical Center (US)
- Northern California Institute for Research and Education (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1002/alz.14311
- Citations
- 3
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Foundation for the National Institutes of Health
- Alzheimer's Association
- Bristol-Myers Squibb
- Alzheimer's Drug Discovery Foundation
- Eli Lilly and Company
- Pfizer
- Merck
- Biogen
- AbbVie
- Meso Scale Diagnostics
- BioClinica
- Novartis Pharmaceuticals Corporation
- Takeda Pharmaceutical Company
- Northern California Institute for Research and Education
- Eisai
- Fujirebio Europe
- Servier
- H. Lundbeck A/S
- IXICO
- National Institutes of Health
- Genentech
- GE Healthcare
- Canadian Institutes of Health Research
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering